Skip to main content

Table 2 Licensed indications of different aromatase inhibitors

From: Update on the use of aromatase inhibitors in early-stage breast cancer

Treatment Newly diagnosed patients Patients currently treated with tamoxifen
Anastrozole Primary adjuvant Unplanned switch following 2 to 3 years of tamoxifen
Exemestane Not applicable Unplanned switch following 2 to 3 years of tamoxifen
Letrozole Primary adjuvant Unplanned switch following 5 years of tamoxifen (extended adjuvant)